1
|
Zhang T, Fu JN, Chen GB, Zhang X. Plac8-ERK pathway modulation of monocyte function in sepsis. Cell Death Discov 2024; 10:308. [PMID: 38961068 PMCID: PMC11222481 DOI: 10.1038/s41420-024-02012-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 05/03/2024] [Accepted: 05/07/2024] [Indexed: 07/05/2024] Open
Abstract
Sepsis, a life-threatening condition caused by infection, is characterized by the dysregulation of immune responses and activation of monocytes. Plac8, a protein, has been implicated in various inflammatory conditions. This study aimed to investigate the effect of Plac8 upregulation on monocyte proliferation and activation in sepsis patients. Peripheral blood samples were collected from healthy individuals and sepsis patients. Monocytes were stimulated with lipopolysaccharide (LPS) to create an in vitro sepsis model, while a murine sepsis model was established using cecal ligation and puncture (CLP). The levels of monocyte markers, proliferation index (PI), and pro-inflammatory cytokines were assessed using flow cytometry and qPCR, respectively. Plac8 and phosphorylated ERK protein levels were determined by western blot, and TNF-α, IL-6, and IL-10 levels were quantified using ELISA. The CCK-8 assay was used to evaluate PBMC proliferation and activation. The results showed that Plac8 was highly expressed in sepsis models, promoting the survival, proliferation, and activation of monocytes. Plac8 upregulation activated the ERK pathway, leading to increased phosphorylation of ERK protein and elevated levels of CD14, CD16, TNF-α, IL-6, Plac8, and IL-10. In sepsis mice, Plac8 overexpression similarly activated the ERK pathway and promoted the survival, proliferation, and activation of monocytes. In conclusion, the upregulation of Plac8 enhances the activation of the ERK pathway and promotes monocyte proliferation and activation in sepsis patients.
Collapse
Affiliation(s)
- Teng Zhang
- Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, 300000, China.
| | - Jing-Nan Fu
- Department of Minimally Invasive Surgery, Characteristics Medical Center of Chinese People Armed Police Force, Tianjin, China
| | - Gui-Bing Chen
- Department of General Surgery, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
| | - Xiu Zhang
- Department of Emergency, Beijing Tsinghua Changgung Hospital, Beijing, 102218, China
| |
Collapse
|
2
|
Kim D, Natu R, Malinauskas R, Baek JH, Buehler PW, Feng X, Qu H, Pinto J, Xu X, Herbertson L. In vitro test methods for evaluating high molecular weight polyethylene oxide polymer induced hemolytic and thrombotic potential. Toxicol In Vitro 2024; 97:105793. [PMID: 38401745 DOI: 10.1016/j.tiv.2024.105793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 02/20/2024] [Indexed: 02/26/2024]
Abstract
To combat opioid abuse, the U.S. Food and Drug Administration (FDA) released a comprehensive action plan to address opioid addiction, abuse, and overdose that included increasing the prevalence of abuse-deterrent formulations (ADFs) in opioid tablets. Polyethylene oxide (PEO) has been widely used as an excipient to deter abuse via nasal insufflation. However, changes in abuse patterns have led to unexpected shifts in abuse from the nasal route to intravenous injection. Case reports identify adverse effects similar to thrombotic thrombocytopenic purpura (TTP) syndrome following the intravenous (IV) abuse of opioids containing PEO excipient. Increased risk of IV opioid ADF abuse compared to clinical benefit of the drug led to the removal of one opioid product from the market in 2017. Because many generic drugs containing PEO are still in development, there is interest in assessing safety consistent with generic drug regulation and unintended uses. Currently, there are no guidelines or in vitro assessment tools to characterize the safety of PEO excipients taken via intravenous injection. To create a more robust excipient safety evaluation tool and to study the mechanistic basis of HMW PEO-induced TMA, a dynamic in vitro test system involving blood flow through a needle model has been developed.
Collapse
Affiliation(s)
- Dongjune Kim
- US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America; US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America
| | - Rucha Natu
- US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America
| | - Richard Malinauskas
- US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America
| | - Jin Hyen Baek
- US FDA, Center for Biologics Evaluation and Research, Division of Blood Components and Devices, Laboratory of Biochemistry and Vascular Biology, Silver Spring, MD, United States of America
| | - Paul W Buehler
- University of Maryland School of Medicine, Center for Blood Oxygen Transport and Hemostasis and the Department of Pathology, Baltimore, MD, United States of America
| | - Xin Feng
- US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America
| | - Haiou Qu
- US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America
| | - Julia Pinto
- US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of New Drug Products, Silver Spring, MD, United States of America
| | - Xiaoming Xu
- US FDA, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, MD, United States of America
| | - Luke Herbertson
- US FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Silver Spring, MD, United States of America.
| |
Collapse
|
3
|
Paone L, Szkolnicki M, DeOre BJ, Tran KA, Goldman N, Andrews AM, Ramirez SH, Galie PA. Effects of Drag-Reducing Polymers on Hemodynamics and Whole Blood-Endothelial Interactions in 3D-Printed Vascular Topologies. ACS APPLIED MATERIALS & INTERFACES 2024; 16:14457-14466. [PMID: 38488736 PMCID: PMC10982934 DOI: 10.1021/acsami.3c17099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 02/22/2024] [Accepted: 03/06/2024] [Indexed: 04/04/2024]
Abstract
Most in vitro models use culture medium to apply fluid shear stress to endothelial cells, which does not capture the interaction between blood and endothelial cells. Here, we describe a new system to characterize whole blood flow through a 3D-printed, endothelialized vascular topology that induces flow separation at a bifurcation. Drag-reducing polymers, which have been previously studied as a potential therapy to reduce the pressure drop across the vascular bed, are evaluated for their effect on mitigating the disturbed flow. Polymer concentrations of 1000 ppm prevented recirculation and disturbed flow at the wall. Proteomic analysis of plasma collected from whole blood recirculated through the vascularized channel with and without drag-reducing polymers provides insight into the effects of flow regimes on levels of proteins indicative of the endothelial-blood interaction. The results indicate that blood flow alters proteins associated with coagulation, inflammation, and other processes. Overall, these proof-of-concept experiments demonstrate the importance of using whole blood flow to study the endothelial response to perfusion.
Collapse
Affiliation(s)
- Louis
S. Paone
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| | - Matthew Szkolnicki
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| | - Brandon J. DeOre
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| | - Kiet A. Tran
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| | - Noah Goldman
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| | - Allison M. Andrews
- Department
of Pathology, Immunology, & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida 32611, United States
| | - Servio H. Ramirez
- Department
of Pathology, Immunology, & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida 32611, United States
| | - Peter A. Galie
- Department
of Biomedical Engineering, Rowan University, Glassboro, New Jersey 08028, United States
| |
Collapse
|
4
|
Baek JH, Shin HKH, Koo SM, Gao Y, Qu H, Feng X, Xu X, Pinto J, Katneni U, Kimchi-Sarfaty C, Buehler PW. Polyethylene Oxide Molecular Size Determines the Severity of Atypical Thrombotic Microangiopathy in a Guinea Pig Model of Acute Intravenous Exposure. Toxicol Sci 2021; 177:235-247. [PMID: 32579216 DOI: 10.1093/toxsci/kfaa099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In 2017, Opana ER was voluntarily removed from the U.S. market based on concerns that its risks outweighed its therapeutic benefits. The data that supported this conclusion were based on postmarketing evaluation that demonstrated increased intravenous abuse associated outbreaks of HIV, hepatitis C, and uniquely, a thrombotic thrombocytopenic purpura (TTP)-like syndrome. In 2017, the cause was mechanistically linked to intravenous exposure of the high-molecular weight polyethylene oxide (PEO), an excipient component of the drug product. However, it was unknown how differing PEO preparations might alter this response in vivo. Knowing the likelihood of a PEO driven atypical thrombotic microangiopathy with hemolytic uremic syndrome (TMA-HUS), this study was specifically designed with the primary objective focused on understanding the impact of PEO molecular weight on TMA-HUS in a guinea pig model of acute repeat PEO (1, 4, and 7 MDa) dosing. Results from this analysis suggest that repeated dosing with PEO 4 and 7 MDa, but not 1 MDa induced a marked intravascular hemolysis with schistocytes, mild anemia, thrombocytopenia, hemoglobinuria, and kidney injury, consistent with observations of a TMA-HUS-like syndrome. Nonetheless, observations of tissue microthrombi, complement or altered von Willebrand factor involvement were not observed, which would be consistent with a definitive TMA. Further, only 7 MDa PEO dosing was associated with marked renal hypoxia. Taken together, this study defines renal injury risk with PEO formulations >1 MDa that is driven by a robust intravascular hemolysis and potentially, tissue hypoxia.
Collapse
Affiliation(s)
- Jin Hyen Baek
- Laboratory of Biochemistry and Vascular Biology, Division of Blood Components and Devices, Office of Blood Research and Review; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Hye Kyung H Shin
- Laboratory of Biochemistry and Vascular Biology, Division of Blood Components and Devices, Office of Blood Research and Review; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Soo Min Koo
- Laboratory of Biochemistry and Vascular Biology, Division of Blood Components and Devices, Office of Blood Research and Review; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Yamei Gao
- Division of Viral Products, Office of Vaccines, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland
| | - Haiou Qu
- Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Xin Feng
- Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Xiaoming Xu
- Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality; Center for Drug Evaluation and Review, FDA, Silver Spring, Maryland
| | - Julia Pinto
- Division of New Drug Product II, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research (CDER), FDA, Silver Spring Maryland
| | - Upendra Katneni
- Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring Maryland
| | - Chava Kimchi-Sarfaty
- Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring Maryland
| | - Paul W Buehler
- Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.,The Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland
| |
Collapse
|